165 related articles for article (PubMed ID: 16172568)
1. The present and future role of (111)In pentetreotide in the PET era.
Rambaldi PF; Cuccurullo V; Briganti V; Mansi L
Q J Nucl Med Mol Imaging; 2005 Sep; 49(3):225-35. PubMed ID: 16172568
[TBL] [Abstract][Full Text] [Related]
2. Nuclear Medicine in Patients with NET: Radiolabeled Somatostatin Analogues and their Brothers.
Cuccurullo V; Prisco MR; Di Stasio GD; Mansi L
Curr Radiopharm; 2017; 10(2):74-84. PubMed ID: 28332450
[TBL] [Abstract][Full Text] [Related]
3.
Hope TA; Calais J; Zhang L; Dieckmann W; Millo C
J Nucl Med; 2019 Sep; 60(9):1266-1269. PubMed ID: 30850506
[TBL] [Abstract][Full Text] [Related]
4. Peptide imaging with somatostatin analogues: more than cancer probes.
Cascini GL; Cuccurullo V; Tamburrini O; Rotondo A; Mansi L
Curr Radiopharm; 2013 Mar; 6(1):36-40. PubMed ID: 23470033
[TBL] [Abstract][Full Text] [Related]
5. Octreoscan Versus FDG-PET for Neuroendocrine Tumor Staging: A Biological Approach.
Squires MH; Volkan Adsay N; Schuster DM; Russell MC; Cardona K; Delman KA; Winer JH; Altinel D; Sarmiento JM; El-Rayes B; Hawk N; Staley CA; Maithel SK; Kooby DA
Ann Surg Oncol; 2015 Jul; 22(7):2295-301. PubMed ID: 25786743
[TBL] [Abstract][Full Text] [Related]
6. Initial staging of lymphoma with octreotide and other receptor imaging agents.
Ferone D; Semino C; Boschetti M; Cascini GL; Minuto F; Lastoria S
Semin Nucl Med; 2005 Jul; 35(3):176-85. PubMed ID: 16098291
[TBL] [Abstract][Full Text] [Related]
7. Imaging of neuroendocrine tumors.
Rufini V; Calcagni ML; Baum RP
Semin Nucl Med; 2006 Jul; 36(3):228-47. PubMed ID: 16762613
[TBL] [Abstract][Full Text] [Related]
8. Gallium-68 PET: a new frontier in receptor cancer imaging.
Al-Nahhas A; Win Z; Szyszko T; Singh A; Nanni C; Fanti S; Rubello D
Anticancer Res; 2007; 27(6B):4087-94. PubMed ID: 18225576
[TBL] [Abstract][Full Text] [Related]
9. Less frequent requests for In-111 pentreotide and its brothers of endocrinological interest.
Cuccurullo V; Cascini GL; Tamburrini O; Mansi L; Rotondo A
Minerva Endocrinol; 2011 Mar; 36(1):41-52. PubMed ID: 21460786
[TBL] [Abstract][Full Text] [Related]
10. Clinical utility of somatostatin receptor scintigraphic imaging (octreoscan) in esthesioneuroblastoma: a case study and survey of somatostatin receptor subtype expression.
Rostomily RC; Elias M; Deng M; Elias P; Born DE; Muballe D; Silbergeld DL; Futran N; Weymuller EA; Mankoff DA; Eary J
Head Neck; 2006 Apr; 28(4):305-12. PubMed ID: 16470879
[TBL] [Abstract][Full Text] [Related]
11. Radioguided surgery with radiolabeled somatostatin analogs: not only in GEP-NETs.
Cuccurullo V; Di Stasio GD; Mansi L
Nucl Med Rev Cent East Eur; 2017; 20(1):49-56. PubMed ID: 28218348
[TBL] [Abstract][Full Text] [Related]
12. Somatostatin receptor expression in non-classical locations - clinical relevance?
Bhanat E; Koch CA; Parmar R; Garla V; Vijayakumar V
Rev Endocr Metab Disord; 2018 Jun; 19(2):123-132. PubMed ID: 30324319
[TBL] [Abstract][Full Text] [Related]
13. Radio-guided surgery in neuroendocrine tumors.
Gulec SA; Baum R
J Surg Oncol; 2007 Sep; 96(4):309-15. PubMed ID: 17726664
[TBL] [Abstract][Full Text] [Related]
14. [Imaging and radioguided surgery of tumors NETs].
SchillirĂ² F; Mallardo V; Manna A; Fontanarosa A; Califano T; Della Vecchia N; Romano G; Di Crescenzo V; Genovese EA
Recenti Prog Med; 2013; 104(7-8):336-9. PubMed ID: 24042403
[TBL] [Abstract][Full Text] [Related]
15. Imaging of neuroendocrine tumours with gamma-emitting radiopharmaceuticals.
Bombardieri E; Coliva A; Maccauro M; Seregni E; Orunesu E; Chiti A; Lucignani G
Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):3-15. PubMed ID: 20168282
[TBL] [Abstract][Full Text] [Related]
16. Preclinical studies of SPECT and PET tracers for NET.
Brom M; Boerman O; Gotthardt M; Oyen WJ
PET Clin; 2014 Jan; 9(1):63-9. PubMed ID: 25029935
[TBL] [Abstract][Full Text] [Related]
17. Nuclear imaging of neuroendocrine tumours.
Sundin A; Garske U; Orlefors H
Best Pract Res Clin Endocrinol Metab; 2007 Mar; 21(1):69-85. PubMed ID: 17382266
[TBL] [Abstract][Full Text] [Related]
18. MIBG and radiolabeled octreotide in neuroendocrine tumors.
Hoefnagel CA
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):137-9. PubMed ID: 9002773
[TBL] [Abstract][Full Text] [Related]
19. Future direction of renal positron emission tomography.
Szabo Z; Xia J; Mathews WB; Brown PR
Semin Nucl Med; 2006 Jan; 36(1):36-50. PubMed ID: 16356795
[TBL] [Abstract][Full Text] [Related]
20. Ten years of experience with MIBG applications and the potential of new radiolabeled peptides: a personal overview and concluding remarks.
Shapiro B
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):150-5. PubMed ID: 9002776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]